REFERENCES
- Baillie T. A., Davis M. R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 1993; 22: 319–325, [INFOTRIEVE], [CSA]
- Baillie T. A., Kassahun K. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv. Exp. Med. Biol. 2001; 50: 45–51, [CSA]
- Day S. H., Mao A., White R., Schulz-Utermoehl T., Miller R., Beconi M. G. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 2005; 52: 278–285, [INFOTRIEVE], [CSA], [CROSSREF]
- Doss G. A., Miller R. R., Zhang Z., Teffera Y., Nargund R. P., Palucki B., Park M. K., Tang Y. S., Evans D. C., Baillie T. A., Stearns R. A. Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline. Chem Res Toxicol. 2005; 18: 271–276, [INFOTRIEVE], [CSA], [CROSSREF]
- Evans D. C., Baillie T. A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug. Discov. Devel. 2005; 8: 44–50, [INFOTRIEVE], [CSA]
- Evans D. C., Watt A. P., Nicoll-Griffith D. A., Baillie T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004; 17: 3–16, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim S., Wu J. Y., Zhang Z., Tang W., Doss G. A., Dean B. J., DiNinno F., Hammond M. L. Estrogen receptor ligands. 12. Synthesis of the major metabolites of an ER-selective, dihydrobenzoxathiin antagonist for osteoporosis. Org. Lett. 2005; 7: 411–414, [INFOTRIEVE], [CSA], [CROSSREF]
- Samuel K., Yin W., Stearns R. A., Tang Y. S., Chaudhary A. G., Jewell J. P., Lanza T., Lin L. S., Hagmann W. K., Evans D. C., Kumar S. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 2003; 38: 211–221, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang C., Subramanian R., Kuo Y., Krymgold S., Lu P., Kuduk S. D., Ng C., Feng D.-M., Elmore C., Soli E., Ho J., Bock M. G., Baillie T. A., Prueksaritanont T. Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates. Chem. Res. Toxicol. 2005; 18: 934–945, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang Z., Chen Q., Li Y., Doss G. A., Dean B. J., Ngui J. S., Silva-Elipe M., Kim S., Wu J. Y., DiNinno F., Hammond M. L., Stearns R. A., Evans D. C., Baillie T. A., Tang W. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem. Res. Toxicol. 2005; 18: 675–685, [INFOTRIEVE], [CSA], [CROSSREF]